Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with an additional office in Dublin, Ireland. The company is dedicated to the development and commercialization of proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Artelo leverages past research and cutting-edge science to accelerate the development of a diverse portfolio of novel therapeutics with the potential to dramatically improve patient care in major markets.
Core to Artelo's mission is their focus on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. This includes cannabinoid-based therapies, both derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The company's flagship program is a patent-protected cannabinoid drug combination treatment aimed at rare and orphan diseases.
One of their notable projects, ART12.11, has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone. This proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) offers biopharmaceutic advantages over standard CBD compositions, showing better pharmacokinetics and improved efficacy in preclinical studies. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.
Another significant program is ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN) and potentially other neuropathic pains. ART26.12 has shown promising results in preclinical studies, reducing pain in models of diabetic neuropathy and chemotherapy-induced peripheral neuropathy.
Artelo is also advancing ART27.13, a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors. This program is currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial, aimed at improving body weight, appetite, muscle degeneration, and quality of life in cancer patients. The company has reported positive progress in clinical trials and aims to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation.
Led by experienced biopharmaceutical executives and backed by collaborations with highly respected researchers and technology experts, Artelo applies rigorous scientific, regulatory, and commercial discipline to develop high-impact therapies. The company maintains a strong presence in global biopharma innovation hubs, ensuring close access to world-class research expertise.
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company, announced its invitation to present at the 2022 Virtual Growth Conference on March 28-30, hosted by Maxim Group LLC and M-Vest. The event will feature company presentations, including updates from CEO Gregory Gorgas. Attendees must register as M-Vest members to participate. Artelo focuses on developing therapeutics that target lipid-signaling pathways and the endocannabinoid system, aiming to address significant medical needs in areas like anorexia, cancer, PTSD, and pain management.
Artelo Biosciences (Nasdaq: ARTL) reported a cash balance of $25.6 million as of December 31, 2021, sufficient to fund operations into H2 2023. The company's net loss for the four-month period was $4.0 million, or $0.12 per share, an increase from a net loss of $2.1 million in the same period in 2020. Key milestones include upcoming Phase 1 data for their ART27.13 program targeting cancer-related anorexia, with significant commercial potential in a market valued over $2 billion. The UK classification of ART27.13 as a non-controlled substance enhances its clinical development prospects.
Artelo Biosciences (NASDAQ: ARTL) announced it has been granted a Notice of Allowance by the U.S. Patent and Trademark Office for patent application 16/835,383, concerning the cocrystal composition of cannabidiol (CBD) under its ART12.11 program. This patent strengthens Artelo's intellectual property portfolio and claims methods for treating various serious conditions, including PTSD and cancer, with a potential patent term extending until 2038. The company aims to utilize its patents to advance treatments for significant unmet medical needs in large markets.
Artelo Biosciences (Nasdaq: ARTL) provided a business update and financial results for the first quarter of its fiscal year ending November 30, 2021. The company is advancing its Cancer Appetite Recovery Study (CAReS) for ART27.13, aiming to complete Phase 1 enrollment by Q1 2022. Financially, Artelo reported a net loss of approximately $2.55 million and operating expenses of $2.55 million, up from $1.44 million year-over-year. Cash and marketable securities stood at $26.4 million as of November 30, 2021, an increase from $10.07 million in August 2021.
Artelo Biosciences (Nasdaq: ARTL) announced that the UK Home Office has reclassified its lead clinical cannabinoid, ART27.13, as 'non-controlled.' This decision allows for unhindered production and supply, enhancing the drug's potential in clinical trials. ART27.13 is currently being evaluated in the Phase 1/2 Cancer Appetite Recovery Study (CAReS), targeting anorexia in cancer patients, a condition affecting up to 60% of advanced-stage patients. The drug has shown promise in previous studies for increasing body weight without CNS side effects.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the virtual H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. Key executives, including Andy Yates and Prof. Saoirse O’Sullivan, will engage in a panel discussing the endocannabinoid system on January 11 at 3:00 PM ET. Additionally, Gregory Gorgas, CEO, will present the company's outlook on January 10, available on-demand to attendees. The conference will spotlight Artelo's development of therapeutics targeting significant health issues, including anorexia and cancer.
Artelo Biosciences (Nasdaq: ARTL) reported financial results for the fiscal year ending August 31, 2021, highlighting a strong balance sheet with over $26.8 million in cash and marketable securities as of November 15, 2021. The company is focused on advancing its lead therapeutic, ART27.13, designed to combat cancer-related anorexia, with Phase 1 data expected in Q1 2022 and Phase 2 data later in the year. Despite a net loss of approximately $7.4 million for 2021, operational progress and clinical trials remain key priorities.
Artelo Biosciences (NASDAQ: ARTL) announced that its CEO, Gregory Gorgas, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on demand for registered attendees starting September 13 at 7:00 AM ET. Artelo aims to develop therapeutics targeting lipid signaling pathways, focusing on unmet medical needs in areas such as cancer and pain management. For more details, the company's presentation can be accessed via its investor relations webpage.
Artelo Biosciences (ARTL) announced findings published in Medical Cannabis and Cannabinoids showing no significant pharmacological differences between natural and synthetic CBD in antiproliferative, anti-inflammatory, or permeability effects. CEO Gregory D. Gorgas emphasized that biopharmaceutical properties are key differentiators for CBD products. Artelo's patented CBD cocrystal, which also includes tetramethylpyrazine (TMP), aims to improve bioavailability and efficacy for treating cancer and other conditions. The study was led by Prof. Saoirse O’Sullivan, a scientific advisor to Artelo.
Artelo Biosciences (NASDAQ: ARTL) announced a R&D showcase focused on its Phase 1b/2a Cancer Appetite Recovery Study (CAReS) for lead drug candidate ART27.13. Hosted by Ladenburg Thalmann on July 28, 2021, at 1 PM EDT, the webinar will feature lead investigator Barry Laird, PhD. Key topics include the etiology of anorexia and treatment challenges. Artelo is dedicated to therapeutics targeting lipid signaling pathways, addressing critical needs in diseases like anorexia and cancer. More details can be found on their website.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
What does Artelo Biosciences do?
Where is Artelo Biosciences headquartered?
What are the main therapeutic areas Artelo Biosciences focuses on?
What is ART12.11?
What is ART26.12?
What is ART27.13?
What recent achievement has ART12.11 demonstrated?
What progress has been made in the ART26.12 program?
Who leads Artelo Biosciences?
Where can I find more information about Artelo Biosciences?
